solutions. You'll design and build device and cloud software to support our current- and next-generation therapeutic devices. Your skillset will play a key role in our efforts to develop, deploy and maintain code that powers best-in-class medical devices for markets across the world.
What will you do? Software design and implementation of Glaukos' current and next generation medical devices, with a particular emphasis on Qt GUI development. Work with UX engineers to design user interfaces, ensuring they are user-friendly, intuitive, and synergistic with device usability features to deliver safe and effective therapeutic therapies in ophthalmology. Software design and implementation
of Glaukos' production software tools as required. Write detailed design documentation and assist in generating clear, concise, testable requirements. Research and backssment of new tools, techniques, and software for leverage in device software or group processes.
Design and execute lab tests, examine, and report on test results. Present and support design conclusions to the cross-functional teams. Advise management during project planning phases and during technical collaborative processes. Mentor junior engineers on technical issues. Work closely with the SWQA team to investigate and resolve issues during testing. How will you get here? A minimum Bachelor of Science degree
in Computer Science, Electrical and Computer Engineering, Physics, Mathematics, or similar technical field.
5+ years of progressive and hands-on experience designing and developing commercial system software for Linux. 5+ years of experience in software engineering, algorithm design, and large-scale system design. Strong knowledge of user interface design concepts and user experience (UI/UX) design. Proficiency in user interface design and development with Qt and QML. Strong working knowledge of C++. Experience building multi-threaded applications. Experience with design patterns, architecture patterns, and OO design concepts. Network and socket programming.
Product development - concept through commercialization. Experience working with git. Generous. Innovative. Leadership-driven. Family-oriented. Socially responsible. These are just a few of the terms our employees use to describe their experiences as a part of the Glaukos family. Those may seem like big aspirations, but here at Glaukos, we recognize the deep significance and profound meaning that comes from knowing that we can make a meaningful difference by helping improve eyesight of people worldwide. And because we're a rapidly growing company with a dynamic, fast-paced culture, individual employees are empowered with more diverse and enriching challenges that might not be possible at a larger company, and more fulfillment in knowing every person and every task is directly tied to making a difference in the life of others.
We offer competitive salary (based on experience), bonus eligibility, medical/dental/vision, life insurance, stock options, 401(k) Employer Match, Employee Stock Purchase Program, generous time off & paid holidays as well as time-off to volunteer in the community, plus the opportunity to work for a company that is pioneering a new glaucoma treatment class!
Moreover, Glaukos Corporation has been Certified as a Great Place to Work the last two years! Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, interaction including interactionual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law. ABOUT US Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and medical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device-the i Stent®-in the United States, followed by our next-generation i Stent inject® device in September 2018 and i Stent inject® W in September 2020. In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus.
And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and medical therapies for glaucoma, corneal health, and retinal diseases. Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol " GKOS" Our global headquarters is located in San Clemente, California with additional locations in Waltham and Burlington, Massachusetts. Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employmentwithout regard to race, color, religion, interaction including interactionual orientation and genderidentity, national origin, disability, protected Veteran Status, or any othercharacteristic protected by applicable federal, state, or local law.
